Google NewsTelix Pharmaceuticals And 2 Other Australian Insider Owned Growth Stocks - Simply Wall Street
Telix Pharmaceuticals And 2 Other Australian Insider Owned Growth Stocks Simply Wall Street
TLX
Pharmaceuticals, Biotechnology & Life Sciences
Telix Pharmaceuticals
- Short interest
- 10.69%
- −0.13 pp 30d
- as of 12 Oct 2026
- Reported shorts
- 36.4M
- Shares on issue
- 340.330M
Telix Pharmaceuticals (TLX) News
Latest articles and price-sensitive announcements with AI sentiment classification.
KalkineWhy is Telix (ASX:TLX) back in focus before EANM in Vienna?
Highlights Telix is presenting a broad slate of research at Europe's major nuclear medicine congress Late-stage programs in brain, kidney and prostate cancer feature prominently Medical technology and AI research also form part of the company's presence Australia's healthcare sector rarely gets a bigger international stage than Europe's flagship nuclear medicine congress, and this year Telix Pharmaceuticals Limited (ASX:TLX) is arriving with an unusually broad showcase. The Melbourne-headquar...
Telix Pharmaceuticals And 2 Other Australian Insider Owned Growth Stocks - Simply Wall Street
Telix Pharmaceuticals And 2 Other Australian Insider Owned Growth Stocks Simply Wall Street
Why Is Telix Pharmaceuticals (ASX:TLX) Back in Focus?
Highlights initial United States commercial doses of a glioma imaging agent have been delivered A new education agreement links the company with a prostate therapy device maker Shares have been among the better performers in a healthcare sector that rebounded Telix Pharmaceuticals (ASX:TLX), the Melbourne-based developer of radiopharmaceutical imaging and therapy products, is back in focus after reporting that the earliest commercial doses of its newly approved glioma imaging agent, Pixclara,...
First U.S. Brain Scan Doses Could Be A Game Changer For Telix Pharmaceuticals (ASX:TLX) - Simply Wall Street
First U.S. Brain Scan Doses Could Be A Game Changer For Telix Pharmaceuticals (ASX:TLX) Simply Wall Street
Why Telix Pharmaceuticals (ASX:TLX) Is Now Judged on Profit and Regulatory Decisions in the ASX 200 - Kalkine
Why Telix Pharmaceuticals (ASX:TLX) Is Now Judged on Profit and Regulatory Decisions in the ASX 200 Kalkine
Could Telix Pharmaceuticals (ASX:TLX) Gain From Pixclara?
Highlight Telix Pharmaceuticals (ASX:TLX) has begun dosing patients in the United States with Pixclara, its FDA-approved PET imaging agent for glioma. The company has also received FDA Fast Track status for its BiPASS prostate cancer imaging programme. Telix's radiopharmaceutical manufacturing and distribution network remains an important part of its operating model. Telix Pharmaceuticals (ASX:TLX) has entered an important commercial phase for Pixclara, following the start of patient dosing in...
Telix Pharmaceuticals (ASX:TLX) Could Be 35% Below Fair Value On Pixclara Launch - Simply Wall Street
Telix Pharmaceuticals (ASX:TLX) Could Be 35% Below Fair Value On Pixclara Launch Simply Wall Street
Motley FoolUBS thinks Telix Pharmaceuticals shares will go how high?
Good news out of the US has led to a share price target upgrade. The post UBS thinks Telix Pharmaceuticals shares will go how high? appeared first on The Motley Fool Australia.
Why Is Telix (ASX:TLX) Merging With Isotope Maker ITM?
Highlights Telix Pharmaceuticals has agreed to acquire Munich-based ITM Isotope Technologies, a large producer of medical radioisotopes, for an upfront sum plus milestone payments. The deal would give Telix control over isotope supply and add a late-stage lutetium-based therapy for neuroendocrine tumours to its pipeline. Owners of Telix are expected to vote on the transaction at a meeting planned for November, with completion targeted before the end of the year. Telix Pharmaceuticals (ASX:TLX...
How Investors Are Reacting To Telix Pharmaceuticals (ASX:TLX) Fast Track Nod - Simply Wall Street
How Investors Are Reacting To Telix Pharmaceuticals (ASX:TLX) Fast Track Nod Simply Wall Street
ASXNotification of cessation of securities - TLX
other announcement
Notification regarding unquoted securities - TLX
other announcement
Application for quotation of securities - TLX
other announcement
Are Telix (ASX:TLX) shares still weighing the ITM merger?
Highlights Telix is working through its agreed acquisition of German isotope producer ITM, a deal that reshapes its supply chain. Part of the consideration depends on US approval of ITM's lead cancer therapy, which received an FDA rejection in August. Approval of the Pixclara brain cancer imaging agent adds to a busy period for the radiopharmaceutical group. Telix Pharmaceuticals (ASX:TLX) remains under the microscope this week as the market continues to digest its agreed merger with ITM Isot...
Telix Pharmaceuticals (ASX:TLX) FDA Fast Track Could Unlock Its Next Major Growth Market - stocksdownunder.com
Telix Pharmaceuticals (ASX:TLX) FDA Fast Track Could Unlock Its Next Major Growth Market stocksdownunder.com
Telix Pharmaceuticals wins FDA Fast Track for BiPASS prostate cancer imaging
Telix Pharmaceuticals shares are in the spotlight after the FDA granted Fast Track for its BiPASS pre-biopsy prostate cancer imaging program. The post Telix Pharmaceuticals wins FDA Fast Track for BiPASS prostate cancer imaging appeared first on The Motley Fool Australia.
Buy, hold, sell: Telix Pharmaceuticals, Qualitas, Greatland Resources shares - The Motley Fool Australia
Buy, hold, sell: Telix Pharmaceuticals, Qualitas, Greatland Resources shares The Motley Fool Australia
FDA Fast Track for BiPASS Pre Biopsy Prostate Imaging
other announcement
Appendix 3Y Change in Director Interest-D Gill
director_dealing announcement
Application for quotation of securities - TLX
other announcement
Telix Pharmaceuticals (ASX:TLX): ITM Deal Shifts Valuation
Highlights Telix Pharmaceuticals proposed ITM combination is reshaping its radiopharmaceutical growth story and cash-flow outlook. Recent Pixclara approval adds another commercial product to Telixs expanding precision medicine portfolio. A discounted cash-flow view highlights the gap between the companys current market valuation and its projected future cash generation. The Australian share market continues to watch healthcare companies closely as commercial execution, regulatory milesto...
What could Telix Pharmaceuticals (ASX:TLX) mean for Healthcare Stocks?
Highlights Telix Pharmaceuticals is expanding its radiopharmaceutical platform through commercial products, clinical programmes and manufacturing capabilities. The proposed ITM Isotope Technologies Munich transaction could broaden Telixs position across the radiopharmaceutical supply chain. Strong revenue growth is being balanced against acquisition funding, integration requirements and continued research and development expenditure. Telix Pharmaceuticals Limited (ASX:TLX) is entering ...
Telix Pharmaceuticals (ASX:TLX) Shares Look Reasonable As Its 188% Run Continues - simplywall.st
Telix Pharmaceuticals (ASX:TLX) Shares Look Reasonable As Its 188% Run Continues simplywall.st
What could Telix (ASX:TLX) reveal about healthcare shares?
Highlights Telix Pharmaceuticals and Ramsay Health Care have taken notably different paths within the Australian healthcare market during twenty twenty-six. Telix has been driven by radiopharmaceutical growth, product development and regulatory progress across its international business. Ramsay has been focused on operational improvement, stronger margins and changes to its international hospital portfolio. The Australian share market has seen a sharp divergence among healthcare companie...
Telix Pharmaceuticals Rebound, As Analyst Upgrades To Outperform - thebull.com.au
Telix Pharmaceuticals Rebound, As Analyst Upgrades To Outperform thebull.com.au
What Does Telix Pharmaceuticals (ASX:TLX) Mean?
Highlights Telix Pharmaceuticals (ASX:TLX) develops radiopharmaceutical products for diagnostic and therapeutic use. Its commercial product approvals support its position within Healthcare Stocks. Regulatory approvals and clinical development progress remain central to its ongoing trajectory. Radiopharmaceuticals occupy a specialised but increasingly significant corner of the healthcare sector, and Telix Pharmaceuticals (ASX:TLX) has emerged as one of the more closely followed names in that s...
What is this broker's view on Telix shares after yesterday's crash?
Here is the latest outlook from Bell Potter. The post What is this broker's view on Telix shares after yesterday's crash? appeared first on The Motley Fool Australia.
Telix Pharmaceuticals Shares Down Double Digits: Here’s Why - thebull.com.au
Telix Pharmaceuticals Shares Down Double Digits: Here’s Why thebull.com.au
Telix shares just crashed 12% on merger news. Time to buy the dip?
Integration, regulatory milestones and dilution are the real tests now. The post Telix shares just crashed 12% on merger news. Time to buy the dip? appeared first on The Motley Fool Australia.
Grant of waivers of Listing Rule 7.3.4
other announcement
Why are Telix Pharmaceuticals shares on the slide today?
Big merger news isn't exciting investors just yet. The post Why are Telix Pharmaceuticals shares on the slide today? appeared first on The Motley Fool Australia.
Telix Pharmaceuticals (ASX:TLX) A US$1.65bn Deal That Could Transform the Radiopharma Story - Stocks Down Under
Telix Pharmaceuticals (ASX:TLX) A US$1.65bn Deal That Could Transform the Radiopharma Story Stocks Down Under
Telix and ITM Join Forces to Create Radiopharma Powerhouse
other announcement
Are Telix shares a buy after its big US FDA news?
Telix announced some big news this week. The post Are Telix shares a buy after its big US FDA news? appeared first on The Motley Fool Australia.
Why Telix Pharmaceuticals Stock Is Up 8.6% And What's Next After FDA Glioma Imaging Approval - simplywall.st
Why Telix Pharmaceuticals Stock Is Up 8.6% And What's Next After FDA Glioma Imaging Approval simplywall.st
Why Could Telix Pharmaceuticals Matter More as Healthcare Holds Up?
Highlights Telix Pharmaceuticals enters the September market backdrop as healthcare demand remains distinct from commodity-driven market pressures. Higher bond yields, elevated oil prices and uneven sector leadership are shaping the broader Australian sharemarket environment. The radiopharmaceutical specialist remains closely linked to commercial execution, regulatory progress and the durability of healthcare demand. The Australian sharemarket is entering a more complicated phase, with e...
Why Is Telix (ASX:TLX) in Focus After Pixclara Approval?
Highlights FDA approval gives Telix (ASX:TLX) a new US-approved imaging product for glioma. Pixclara expands Telixs radiopharmaceutical imaging portfolio. Attention now turns to US commercial rollout and progress across the broader pipeline. What Is Pixclara? Pixclara, also known as TLX101-Px or floretyrosine F 18, is a positron emission tomography imaging drug designed for glioma, a type of brain cancer. The product uses fluorine-18, a radioactive isotope, to support PET imaging. According to...
Buy, hold, sell: Domino’s Pizza, Telix Pharmaceuticals, Westfarmers shares - The Motley Fool Australia
Buy, hold, sell: Domino’s Pizza, Telix Pharmaceuticals, Westfarmers shares The Motley Fool Australia
Why are Telix Pharmaceuticals shares charging higher today?
A key approval is good news for this drug developer. The post Why are Telix Pharmaceuticals shares charging higher today? appeared first on The Motley Fool Australia.
Will Telix (ASX:TLX) Clear Its Brain Imaging Review Hurdle?
Highlights A resubmitted application for the group's brain tumour imaging agent was accepted by the United States regulator with a decision date set. [ASX 100] Quarterly revenue climbed across the precision medicine arm as prescribed dose volumes expanded in the United States. A separate kidney cancer imaging application is being prepared for resubmission following a regulatory extension. Telix Pharmaceuticals (ASX:TLX) is approaching a decision point on its brain tumour imaging agent, after ...
Why Is Telix (ASX:TLX) Making Waves After Pixclara Approval?
Highlights Telix Pharmaceuticals has secured US FDA approval for Pixclara, its PET imaging drug for glioma, marking a major regulatory milestone. The approval gives Telix a new precision-medicine product focused on brain cancer imaging and expands its presence in the US market. Pixclara adds another commercial opportunity to Telixs radiopharmaceutical portfolio while the company continues developing products across several cancer indications. Telix Pharmaceuticals (ASX:TLX) has entered a...
Telix Pharmaceuticals (ASX:TLX) Wins FDA Approval for Pixclara Is a Major Re-Rate Coming? - Stocks Down Under
Telix Pharmaceuticals (ASX:TLX) Wins FDA Approval for Pixclara Is a Major Re-Rate Coming? Stocks Down Under
Telix Pharmaceuticals shares: FDA approves Pixclara brain cancer drug
Telix Pharmaceuticals’ US FDA approval for Pixclara is a first for glioma imaging, expanding its precision medicine offerings. The post Telix Pharmaceuticals shares: FDA approves Pixclara brain cancer drug appeared first on The Motley Fool Australia.
Application for quotation of securities - TLX
other announcement
FDA Approves Telix Brain Cancer Imaging Drug Pixclara
other announcement
Telix Pharmaceuticals (ASX: TLX): BiPASS Phase 3 Enrollment Completes and Maps an FDA Pathway - Kalkine
Telix Pharmaceuticals (ASX: TLX): BiPASS Phase 3 Enrollment Completes and Maps an FDA Pathway Kalkine
Telix Pharmaceuticals (ASX:TLX) September 11 PIXCLARA Decision Could Trigger the Next Re-Rate - Stocks Down Under
Telix Pharmaceuticals (ASX:TLX) September 11 PIXCLARA Decision Could Trigger the Next Re-Rate Stocks Down Under
Telix Pharmaceuticals (ASX:TLX): Is Pixclara Hype Priced In?
Highlights Telix Pharmaceuticals has completed enrolment in its Phase Three BiPASS study, adding another important milestone to its oncology development pipeline. Attention is turning towards the upcoming US regulatory decision for Pixclara, the company's brain cancer imaging agent. Recent share price momentum has increased focus on Telix's valuation as its commercial business and expanding clinical pipeline develop together. Telix Pharmaceuticals (ASX:TLX) is entering a closely watched ...
Telix Pharmaceuticals (ASX:TLX) Nears A Pixclara Decision, Is The Upside Already Priced In? - simplywall.st
Telix Pharmaceuticals (ASX:TLX) Nears A Pixclara Decision, Is The Upside Already Priced In? simplywall.st
Does Telix Pharmaceuticals' Pipeline Progress Hint at a New Strategic Phase?
Highlights Telix Pharmaceuticals (ASX:TLX) has completed enrollment in a pivotal Phase 3 trial for its PSMA-PET imaging agents The company recently appointed an experienced life sciences executive as Chair of the Board, reinforcing governance An upcoming FDA decision on a separate brain-cancer imaging agent adds a further near-term catalyst to watch Telix Pharmaceuticals (ASX:TLX) has completed enrollment of 350 patients in its pivotal Phase 3 BiPASS trial assessing its Illuccix and Gozellix P...
Telix shares are up 98%: Is there more upside to come?
The bull case remains compelling: rapid growth, rising profits and broker optimism. The post Telix shares are up 98%: Is there more upside to come? appeared first on The Motley Fool Australia.
TELIX Pharmaceuticals (ASX: TLX): Shares Edge Higher as Commercial Growth and Pipeline Progress Continue - Kalkine
TELIX Pharmaceuticals (ASX: TLX): Shares Edge Higher as Commercial Growth and Pipeline Progress Continue Kalkine
Telix Completes Enrollment in Phase 3 BiPASS Study
other announcement
Is Putting Telix (ASX:TLX) on the Healthcare Stocks Radar?
Highlights Telix lifted half-year group revenue at a brisk rate against the prior corresponding period. Trading is tracking toward the upper end of the full-year revenue guidance range. Group gross margin improved, with precision medicine carrying the strongest margin profile. Telix Pharmaceuticals (ASX:TLX), the Melbourne-based radiopharmaceutical group whose imaging agents are used widely across United States cancer clinics, lifted half-year group revenue at a brisk clip and signalled it is...
Telix Pharmaceuticals Shares Hit A Wall of Resistance: What Happened? - thebull.com.au
Telix Pharmaceuticals Shares Hit A Wall of Resistance: What Happened? thebull.com.au
Telix Pharmaceuticals (ASX:TLX) Shares Cool As Profit Momentum Meets Pipeline Delays - simplywall.st
Telix Pharmaceuticals (ASX:TLX) Shares Cool As Profit Momentum Meets Pipeline Delays simplywall.st
Telix shares are tumbling. Is the stock finally at fair value?
Telix's sell-off reflects valuation, competition, and heightened growth expectations. The post Telix shares are tumbling. Is the stock finally at fair value? appeared first on The Motley Fool Australia.